首页|期刊导航|中华医学杂志（英文版）|Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs.chemotherapy alone in HER2(-)locally advanced gastric cancer:A propensity score-matched cohort study

Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs.chemotherapy alone in HER2(-)locally advanced gastric cancer:A propensity score-matched cohort study

Gehan Xu Tianjiao Liu Jingyi Shen Quanlin Guan

中华医学杂志（英文版）2025，Vol.138Issue(4)：459-471,13.

中华医学杂志（英文版）2025，Vol.138Issue(4)：459-471,13.DOI:10.1097/CM9.0000000000003028

Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs.chemotherapy alone in HER2(-)locally advanced gastric cancer:A propensity score-matched cohort study

Gehan Xu ¹Tianjiao Liu ²Jingyi Shen ¹Quanlin Guan³

作者信息

1. The First Clinical Medical College of Lanzhou University,Lanzhou,Gansu 730000,China
2. Department of Medical Data,Beijing Yiyong Technology Co.,Ltd.,Beijing 100102,China
3. Department of Oncology Surgery,The First Hospital of Lanzhou University,Lanzhou,Gansu 730000,China
折叠

摘要

关键词

Gastric cancer/Neoadjuvant therapy/Immune checkpoint inhibitor/Chemotherapy/Propensity score matching

Key words

Gastric cancer/Neoadjuvant therapy/Immune checkpoint inhibitor/Chemotherapy/Propensity score matching

引用本文复制引用

Gehan Xu,Tianjiao Liu,Jingyi Shen,Quanlin Guan..Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs.chemotherapy alone in HER2(-)locally advanced gastric cancer:A propensity score-matched cohort study[J].中华医学杂志（英文版）,2025,138(4):459-471,13.

基金项目

This work was supported by grants from the Gansu Provincial Key Research and Development Project-Social Development Category(No.20YF3FA029),the Gansu Science and Technology Project(No.20JR10RA672),and the First Hospital of Lanzhou University Hospital Fund(No.ldyyyn2021-1). （No.20YF3FA029）

中华医学杂志（英文版）

ISSN：0366-6999

访问量0

下载量0

段落导航